Literature DB >> 20607625

Vector insert-targeted integrative antisense expression system for plasmid stabilization.

Jeremy M Luke1, Aaron E Carnes, Clague P Hodgson, James A Williams.   

Abstract

Some DNA vaccine and gene therapy vector-encoded transgenes are toxic to the E. coli plasmid production host resulting in poor production yields. For plasmid products undergoing clinical evaluation, sequence modification to eliminate toxicity is undesirable because an altered vector is a new chemical entity. We hypothesized that: (1) insert-encoded toxicity is mediated by unintended expression of a toxic insert-encoded protein from spurious bacterial promoters; and (2) that toxicity could be eliminated with antisense RNA-mediated translation inhibition. We developed the pINT PR PL vector, a chromosomally integrable RNA expression vector, and utilized it to express insert-complementary (anti-insert) RNA from a single defined site in the bacterial chromosome. Anti-insert RNA eliminated leaky fluorescent protein expression from a target plasmid. A toxic retroviral gag pol helper plasmid produced in a gag pol anti-insert strain had fourfold improved plasmid fermentation yields. Plasmid fermentation yields were also fourfold improved when a DNA vaccine plasmid containing a toxic Influenza serotype H1 hemagglutinin transgene was grown in an H1 sense strand anti-insert production strain, suggesting that in this case toxicity was mediated by an antisense alternative reading frame-encoded peptide. This anti-insert chromosomal RNA expression technology is a general approach to improve production yields with plasmid-based vectors that encode toxic transgenes, or toxic alternative frame peptides.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20607625     DOI: 10.1007/s12033-010-9310-5

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  18 in total

1.  The instability of a recombinant plasmid, caused by a prokaryotic-like promoter within the eukaryotic insert, can be alleviated by expression of antisense RNA.

Authors:  J Fütterer; K Gordon; P Pfeiffer; T Hohn
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

2.  Insertion of natural intron 6a-6b into a human cDNA-derived gene therapy vector for cystic fibrosis improves plasmid stability and permits facile RNA/DNA discrimination.

Authors:  A C Boyd; F Popp; U Michaelis; H Davidson; H Davidson-Smith; A Doherty; G McLachlan; D J Porteous; S Seeber
Journal:  J Gene Med       Date:  1999 Sep-Oct       Impact factor: 4.565

3.  Inactivation of the transcriptional-dependent inhibition of plasmid replication: a selection method for cloning large DNA fragments.

Authors:  P Engels; P Meyer
Journal:  Biotechniques       Date:  1993-03       Impact factor: 1.993

4.  Construction and characterization of a novel cross-regulation system for regulating cloned gene expression in Escherichia coli.

Authors:  W Chen; P T Kallio; J E Bailey
Journal:  Gene       Date:  1993-08-16       Impact factor: 3.688

5.  Toxicity of an overproduced foreign gene product in Escherichia coli and its use in plasmid vectors for the selection of transcription terminators.

Authors:  J Brosius
Journal:  Gene       Date:  1984-02       Impact factor: 3.688

6.  Cloning of Streptococcus pneumoniae DNA fragments in Escherichia coli requires vectors protected by strong transcriptional terminators.

Authors:  J D Chen; D A Morrison
Journal:  Gene       Date:  1987       Impact factor: 3.688

Review 7.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

Review 8.  Strategies for achieving high-level expression of genes in Escherichia coli.

Authors:  S C Makrides
Journal:  Microbiol Rev       Date:  1996-09

Review 9.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

10.  Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes.

Authors:  James A Williams; Jeremy Luke; Sarah Langtry; Sheryl Anderson; Clague P Hodgson; Aaron E Carnes
Journal:  Biotechnol Bioeng       Date:  2009-08-15       Impact factor: 4.530

View more
  1 in total

Review 1.  Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.

Authors:  James A Williams
Journal:  Vaccines (Basel)       Date:  2013-06-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.